PepGen, Inc. (NASDAQ:PEPG) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET

Company Participants

Emiko Bryant - Chief of Staff

James McArthur - President and CEO

Michelle Mellion - SVP and Head, Clinical Development

Noel Donnelly - CFO

Conference Call Participants

Jenny Gonzalez-Armenta - Leerink Partners

James Condulis - Stifel

Tazeen Ahmad - Bank of America

Laura Chico - Wedbush

Ananda Ghosh - H.C. Wainwright & Company

Operator

Good afternoon, and welcome to PepGen's Fourth Quarter and Full Year 2023 Earnings Call to discuss its financial results and recent corporate developments.

At this time all participants are on a listen-only mode. Following the manager's prepared remarks we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, March 6, 2024.

I would now like to turn the conference call over to Emiko Bryant, Chief of Staff of PepGen. Emiko, please go ahead.

Emiko Bryant

Thank you, operator. Good afternoon, everyone, and thank you for joining today's call. Earlier today, we released our financial results for the fourth quarter and full year 2023 and provided an update on recent corporate developments. The press release and our 10-K filed with the SEC this afternoon outlining our financial results are both available on our website at pepgen.com.

Joining me on the call today are James McArthur, PhD, President and Chief Executive Officer; Dr. Michelle Mellion, Senior Vice President, Head of Clinical Development; and Noel Donnelly, Chief Financial Officer.

As a reminder, we will be making forward-looking statements regarding our financial outlook in addition to regulatory and product development plans and research activities. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent 10-K on file with the SEC.

PepGen does not undertake any obligation to publicly update its forward-looking statements as a result of new information, future events or changes in its expectations.

I will now turn the call over to our CEO, James McArthur. James?

James McArthur

Thank you, Emiko, and good afternoon, everyone. PepGen made meaningful progress over the course of 2023, including the initiation of our first inpatient clinical trials evaluating programs derived from PepGen Enhanced Delivery Oligonucleotide, or EDO, cell-penetrating peptide platform in two neuromuscular diseases with high unmet medical need. Our lead clinical program, PGN-EDO51 or EDO51 is designed for the treatment of patients with Duchenne Muscular Dystrophy, also known as DMD, whose disease is amenable to an exon 51-skipping approach. As a reminder, an estimated 13% people with DMD or approximately 4,200 individuals in the U.S. and EU have a mutation amenable to an exon 51-skipping approach.